ArticleAnnals of general psychiatry2026
Validating objective and scalable speech markers of depression across two independent psychiatric cohorts.
Article in Annals of general psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUsing speech as objective markers for major depressive disorder (MDD) has shown promise, yet their generalizability across clinical settings remains largely unvalidated.
objectiveThis study aimed to validate previously identified speech markers of depressive symptoms in an independent clinical cohort, thereby assessing their reproducibility and robustness for cross-site application.
methodsSpeech data from two independent psychiatric cohorts (RWTH Aachen and University of Oldenburg, Germany) were analyzed, comprising 135 participants (71 healthy controls, 64 MDD patients). Participants completed a positive and a negative storytelling task, over 80 temporal, lexical, and spectral speech features were extracted from the acoustic signal. Statistical analyses assessed group differences and correlations with Beck Depression Inventory (BDI-II) scores. Machine learning models trained on the Aachen data were tested on the Oldenburg cohort.
resultsSeveral temporal and spectral speech features, including utterance duration, pause duration, and MFCCs, were consistently associated with MDD diagnosis and symptom severity across both cohorts. Machine learning models trained on Aachen data achieved a classification accuracy (ROC-AUC) of 0.63 on the Oldenburg sample, demonstrating above-chance but modest transfer performance. Voice quality features (shimmer, jitter) showed more variable associations: partial correlations indicated some significant effects (e.g., shimmer and jitter during positive storytelling), whereas moderation analyses revealed interaction effects, particularly for shimmer and jitter in negative storytelling, where MDD patients exhibited higher values in the Aachen cohort but lower values in the Oldenburg cohort compared to healthy controls.
conclusionsThe study indicates that temporal and spectral markers of speech are relatively robust across independent clinical samples, whereas voice quality markers (shimmer, jitter) show site-dependent inconsistencies, acting as technical artifacts of varying recording conditions rather than robust biomarkers. While current speech-based classifiers remain less accurate than established self-report measures, their integration with clinical scores offers a more balanced trade-off between sensitivity and specificity. Future work should prioritize systematic evaluation across elicitation tasks, languages, and longitudinal settings to delineate which speech features are transferable and which are task-specific.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.